Sichuan Institute for Drug Control, Chengdu, 611731, China.
Chengdu Kanghong Pharmaceutical Co. Ltd, Chengdu, 610037, China.
Bioanalysis. 2024 Jun 2;16(11):535-544. doi: 10.1080/17576180.2024.2344345. Epub 2024 Jun 6.
A new, selective and simple UPLC-MS/MS method was developed and validated for the determination of lifitegrast in human plasma and tear in order to obtain PK data. Lifitegrast-d4 solutions were added in the samples, and then were extracted and transferred to a UPLC vial. The respective working ranges were 25.00-2000.00 pg/ml in plasma and 4.00-1000.00 μg/ml in tear. The fully validated method complied with existing regulatory criteria for accuracy and precision, recovery, etc. It was applied to plasma and tear samples, which were from a clinical study, successfully. This method is useful in the evaluation of lifitegrast in plasma and tear.
建立并验证了一种新的、选择性好且简单的 UPLC-MS/MS 法,用于测定人血浆和泪液中的利发替斯汀,以获得 PK 数据。在样品中加入利发替斯汀-d4 溶液,然后进行提取并转移到 UPLC 小瓶中。血浆中的相应工作范围为 25.00-2000.00 pg/ml,泪液中的相应工作范围为 4.00-1000.00 μg/ml。该完全验证的方法符合准确度和精密度、回收率等现有监管标准。该方法已成功应用于临床研究中的血浆和泪液样品的测定。该方法可用于评价利发替斯汀在血浆和泪液中的浓度。